Journal article
Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
Abstract
PURPOSE: Cyclophosphamide, epirubicin, and fluorouracil (CEF), compared with classical cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy. has lead to an improvement in relapse-free and overall survival in premenopausal women with node-positive breast cancer. We undertook this analysis to more accurately define the estimate of risk of secondary acute leukemia (sAL) following epirubicin-containing chemotherapy regimens.
PATIENTS …
Authors
Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
Journal
Journal of Clinical Oncology, Vol. 21, No. 16, pp. 3066–3071
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
August 15, 2003
DOI
10.1200/jco.2003.08.137
ISSN
0732-183X